

2736-6730

Safety Assessment for Pharmaceuticals

Edited by
Shayne C. Gad

IBS
Raleigh, North Carolina



VAN NOSTRAND REINHOLD

I(T)P A Division of International Thomson Publishing Inc.

New York • Albany • Bonn • Boston • Detroit • London • Madrid • Melbourne
Mexico City • Paris • San Francisco • Singapore • Tokyo • Toronto

Contents

List of Contributors xiii

Preface xv

1 Strategy and Phasing for Drug Safety Evaluation in the Discovery and Development of Pharmaceuticals 1

Shayne C. Gad

Introduction 1

Regulatory Requirements 4

Essential Elements of Project Management 9

Screens: Their Use and Interpretation in Safety Assessment 9

Strategy and Phasing 17

Special Cases in Safety Assessment 24

Summary 25

References 25

2 Information Sources: Building and Maintaining Data Files 29

David L. Larson, Ted O. King, Roger P. Nelson, and Shayne C. Gad

Traditional Information Sources 29

New Sources 34

Conclusions 39

References 41

3 Screens in Safety and Hazard Assessments 43

Shayne C. Gad

- Introduction 43
- Characteristics of Screens 45
- Uses of Screens 48
- Types of Screens 49
- Criterion: Development and Use 51
- Analysis of Screening Data 53
- References 58

4 Acute Toxicity Testing in Drug Safety Evaluation 61

Christopher P. Chengelis

- Introduction 61
- Range-Finding Studies 62
- Acute Systemic Toxicity Characterization 76
- Screens 99
- References 105

5 Subchronic and Chronic Toxicity Studies 111

Shayne C. Gad

- Objectives 111
- Regulatory Considerations 113
- Study Design and Conduct 115
- Study Interpretation and Reporting 127
- References 127

6 Developmental and Reproductive Toxicity Testing 129

Robert L. Clark

- Introduction 129
- ICH Study Designs 131
- Methodological Issues 137
- Data Interpretation 148
- In Vitro* Tests for Developmental Toxicity 159
- Appraisal of Current Approaches for Determining Developmental and Reproductive Hazards 160
- References 161

7 Carcinogenicity Studies 167*Linval R. DePass*

- Introduction 167
- Species and Strain 167
- Animal Husbandry 170
- Dose Selection 171
- Group Size 174
- Route of Administration 174
- Study Duration 175
- Survival 175
- Statistical Analysis 177
- Interpretation of Results 179
- Conclusions 181
- References 181

8 Safety Assessment of Inhalant Drugs 185*Basil K. J. Leong*

- Introduction 185
- The Pulmonary System 185
- Penetration and Absorption of Inhaled Gases and Vapors 186
- Deposition of Inhaled Aerosols 189
- Absorption and Clearance of Inhaled Aerosols 190
- Pharmacotoxicity of Inhaled Aerosols 191
- Methods for Safety Assessment of Inhaled Medicinal Aerosols 193
- Parameters of Toxicity Evaluation 196
- Inhalation Exposure Techniques 203
- The Utility of Toxicity Data 206
- References 207

9 Irritation and Local Tissue Tolerance in Pharmaceutical Safety Assessment 217*Shayne C. Gad*

- Primary Dermal Irritation Test 217
- Other Nonparenteral Route Irritation Tests 221
- Factors Affecting Irritation Responses and Test Outcome 221
- Problems in Testing (and Their Resolutions) 223
- Ocular Irritation Testing 223
- Parenteral Irritation/Tolerance 226
- References 240

10 Routes, Formulations, and Dose Designs 243

Shayne C. Gad

Mechanisms 244

Common Routes 249

Formulation of Test Materials 272

Dosing Calculations 287

Calculating Material Requirements 288

Appendix: Vehicles and Excipients 289

References 296

11 Occupational Toxicology in the Pharmaceutical Industry 301

Diana M. Gáler

Introduction 301

Occupational Toxicology versus Drug Safety Evaluation 302

Regulatory Pressures in the United States and the European
Community 305

Organizational Structure 307

Activities 308

Future Issues in Occupational Toxicology in the Pharmaceutical
Industry 321

Conclusion 322

References 322

12 Immunotoxicology in Pharmaceutical Development 325

Peggy J. Guzzie

Introduction 325

Overview of the Immune System 328

Immunotoxic Effects 334

Evaluation of the Immune System 353

Approaches 371

Problems and Future Directions 376

References 379

13 Special Case: Nonrodent Studies 387

Gillian C. Haggerty

Introduction 387

Comparison between Rodent and Nonrodent Experimental Design	387
Nonrodent Models	389
Summary	404
References	404

14 The Application of *In Vitro* Techniques in Drug Safety Assessment 407

Patricia D. Williams, Joseph F. Sina, and Teresa A. Smolarek

Introduction	407
Industrial Applications	409
Validation	440
The Future	442
References	444

Appendix: ICH Harmonized Tripartite Guideline	459
--	------------

Index	481
--------------	------------